About TirzepatideReview.com

Who we are

TirzepatideReview.com publishes editorial reviews and rankings of tirzepatide telehealth providers, addressing a question the existing telehealth review landscape doesn't answer well: which tirzepatide telehealth provider is actually right for me? The editorial team is led and medically reviewed by Dr. Parmis Every provider is scored against the published v4.1 seven-category weighted rubric, applied uniformly. Rankings are based on the methodology, and providers cannot pay to appear higher in organic comparisons.

Our scope

This site exclusively covers tirzepatide — the dual GLP-1/GIP receptor agonist developed by Eli Lilly and Company. We cover:

• Brand-name tirzepatide: Mounjaro® (T2D) and Zepbound® (chronic weight management)
• Compounded tirzepatide: Dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities
• U.S. telehealth providers: 10+ providers prescribing tirzepatide reviewed in detail
• Comparative context: Where appropriate, comparison-class GLP-1 medications (semaglutide, liraglutide, dulaglutide)

Editorial team

Dr. Parmis — Editorial Lead

Dr. Parmis · Medical Researcher, Western University of Health Sciences. Leads research and writing for TirzepatideReview.com — provider scoring, clinical-evidence summaries, pharmacy-policy analysis. Does not receive compensation from any telehealth provider reviewed on this site.

Dr. Parmis — Editorial Lead

Dr. Parmis leads editorial research and medical review for TirzepatideReview.com. Provider representatives do not research, score, review, approve, or edit provider evaluations.

Why we rank NexLife #1

NexLife earned the #1 editorial position (94/100) on three publicly verifiable criteria from our rubric:

• Flat-rate pricing. NexLife's monthly cost stays the same from the starting 2.5 mg dose to maintenance 15 mg. Some competitors price by dose, so the monthly bill rises as the dose climbs; the price index flags each one.
• Pharmacy sourcing transparency. NexLife names the pharmacies that fill its prescriptions on its plan pages.
• MD/DO clinical oversight. NexLife names its medical director and states that licensed clinicians review every intake.

Full rubric on the Editorial Standards page.

Ownership & affiliate disclosure

Publisher. TirzepatideReview.com is owned and published by Ronika Partners LLC. It is affiliate-supported: we may earn a commission when a reader enrolls with a provider through a link on this site, at no additional cost to the reader.

Affiliate relationships. This site may earn commissions from links to any provider it lists; such relationships can exist with one or more listed providers, can change, and never decide a position. This page does not say which providers pay commissions. Outbound provider links carry rel="nofollow" and any paid placement would be labeled where it appears.

What a commission cannot do. Commercial relationships cannot buy a ranking. Positions follow the v4.1 methodology published in advance, applied uniformly to every provider, and any program, the pick included, can lose under it. Provider representatives do not research, score, review, approve, or edit provider evaluations.

Corrections. If you believe a commercial relationship has influenced a page, email corrections@tirzepatidereview.com. We review documented complaints within five business days and log material corrections on the affected page.

What this site is not

• Not a healthcare provider. We do not employ physicians, prescribe medications, or operate a pharmacy.
• Not a pharmacy or insurance broker.
• Not a substitute for medical advice. Information is educational.
• Not affiliated with the FDA, FTC, Eli Lilly and Company, or any government agency.

Contact & corrections

For corrections, provider-data updates, or to suggest a provider for review, email tirzepatidereview@gmail.com. We aim to review documented corrections within five business days.